Save time and get answers to complex questions with AI chat
Patent expiration eu dabrafenib?Complera manufacturer?The expiration date of the key patent for guselkumab?How to apply for vascepa's patient assistance?Is januvia still on the market?
See the DrugPatentWatch profile for Nplate
Nplate is a medicine made by Amgen. It contains romiplostim, a thrombopoietin receptor agonist used to treat certain types of chronic immune (idiopathic) thrombocytopenic purpura (ITP) in people whose platelet counts do not respond adequately to other therapies [1].
Nplate works by stimulating the thrombopoietin receptor on cells involved in platelet production. This signaling increases platelet count [1].
Nplate is given as an injection [1].
Nplate is used in chronic immune thrombocytopenia (chronic ITP) when platelet counts remain too low despite other treatments [1].
Common risks and important safety considerations for medicines in this class include blood clotting risk and platelet count-related issues; specific risks are detailed in the product information and prescribing guidance for Nplate [1].
You can review Amgen’s product materials and the prescribing information for Nplate on Amgen’s site and associated regulatory labeling resources [1].
Other Questions About Nplate :